Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Autoantibody Serology in Cutaneous Lupus, Dermatomyositis, and Systemic Sclerosis
Description
The talk reviewed how autoantibody serology is used to evaluate cutaneous lupus erythematosus, dermatomyositis, and systemic sclerosis, emphasizing that results must be interpreted in clinical context. It explained how ANA testing is performed by indirect immunofluorescence on HEp-2 cells, why titers and patterns can vary between readers, and why a positive ANA is common even in healthy people or with increasing age and certain medications. The speaker highlighted when to order additional tests such as anti-dsDNA, anti-Smith, SSA/Ro, SSB, RNP, antiphospholipid antibodies, antihistone antibodies, and anti-centromere, and noted which antibodies are linked to specific disease features such as lupus nephritis, photosensitivity, Sjogren’s, neonatal lupus/heart block, mixed connective tissue disease, and systemic sclerosis. A key point was that anti-histone antibodies are not specific for drug-induced lupus, and that serologies often should not be repeated routinely except when monitoring dsDNA and complements or when the clinical picture changes. For dermatomyositis, the talk reviewed myositis-specific and antisynthetase antibodies and stressed that commercial line blot and enzyme assays can miss antibodies compared with immunoprecipitation gold standards, leading to false negatives. For systemic sclerosis, it summarized the role of ANA patterns, anti-centromere, SCL-70, RNA polymerase III, and the fact that a minority of patients are seronegative.
View moreConclusions
- For cutaneous lupus, ANA is a useful first-line test, but results must be interpreted in clinical context because low-titer positivity is common in healthy people and ANA-negative lupus can still occur, especially with SSA/Ro antibodies.
- ANA testing should generally not be repeated routinely, while anti-dsDNA and complement levels are the main serologies that help monitor lupus disease activity over time.
- Secondary serologies such as SSA/SSB, Smith, RNP, and antiphospholipid antibodies should be ordered selectively based on phenotype, pregnancy considerations, clotting history, and overlap features.
- A positive ANA pattern can sometimes add useful information, but specific autoantibody assays have largely replaced pattern interpretation for most diseases.
- Anti-Ro antibodies have important disease associations, with Ro52 and Ro60 linked to different autoimmune phenotypes and Ro positivity being especially important in pregnancy because it relates to neonatal lupus and congenital heart block risk.
- Hydroxychloroquine in Ro-positive pregnancy may substantially reduce the risk of fetal heart block in subsequent pregnancies.
- Anti-histone antibodies are not specific for drug-induced lupus because they can also be present in idiopathic lupus, so dsDNA and the overall clinical picture are needed to distinguish them.
- Drug-induced lupus and drug-induced cutaneous lupus have drug-specific serologic and clinical patterns, so the offending medication and timing are critical to diagnosis.
- Antiphospholipid syndrome evaluation requires lupus anticoagulant, anticardiolipin, and beta-2 glycoprotein antibodies, with persistence on repeat testing at least 12 weeks apart required for diagnosis.
- In dermatomyositis, myositis-specific autoantibodies are clinically meaningful for phenotype and risk stratification, including cancer-associated subsets such as TIF1-gamma.
- Commercial myositis antibody panels can miss cases because line blot and enzyme immunoassays are less sensitive than immunoprecipitation gold-standard methods, so false negatives remain a major limitation.
- In systemic sclerosis, ANA plus antibodies such as centromere, Scl-70/topoisomerase I, RNA polymerase III, and U1-RNP help define subsets and complications, but a minority of patients remain seronegative.
- Lazar S, Kahlenberg JM. Systemic lupus erythematosus: new diagnostic and therapeutic approaches. Annual Review of Medicine. 2023 Jan 27;74:339-52.#10.1146/annurev-med-043021-032611
- Menendez A. et al. Autoimmunity. 2013;46(1):32-39.
- Merola, JF. Drug-Induced Lupus Erythematosus. Chapter in: Schur PH, Massarotti E. Clinical Management of Systemic Lupus Erythematosus. Second Edition.
- Merola and a 2021 Journal of Clinical Rheumatology article.
- Gono et al. Semin Arthritis Rheum. 2025 Oct 27;75:152858.